Biosergen AB (BIOSGN.ST)
SEK 0.33
(-0.6%)
SEK 0.33
(-0.6%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 26.8 Million SEK | -20.8% |
| 2022 | 33.84 Million SEK | -0.15% |
| 2021 | 33.9 Million SEK | 444.49% |
| 2020 | 6.22 Million SEK | -4.49% |
| 2019 | 6.51 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 6.79 Million SEK | 2.66% |
| 2024 Q2 | 5.72 Million SEK | -15.74% |
| 2023 Q2 | 8.02 Million SEK | 66.94% |
| 2023 Q4 | 6.62 Million SEK | -12.12% |
| 2023 Q3 | 7.53 Million SEK | -6.14% |
| 2023 Q1 | 4.8 Million SEK | -25.72% |
| 2023 FY | 34.77 Million SEK | 2.73% |
| 2022 Q1 | 5.01 Million SEK | -48.26% |
| 2022 FY | 33.84 Million SEK | -0.15% |
| 2022 Q4 | 6.47 Million SEK | -55.4% |
| 2022 Q3 | 14.51 Million SEK | 85.12% |
| 2022 Q2 | 7.84 Million SEK | 56.26% |
| 2021 Q4 | 9.69 Million SEK | 6.41% |
| 2021 Q2 | 12.54 Million SEK | 51.04% |
| 2021 FY | 33.9 Million SEK | 444.49% |
| 2021 Q1 | 8.3 Million SEK | 0.0% |
| 2021 Q3 | 9.11 Million SEK | -27.34% |
| 2020 FY | 6.22 Million SEK | -4.49% |
| 2019 FY | 6.51 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | 1.51 Billion SEK | 98.23% |
| Camurus AB (publ) | 1.05 Billion SEK | 97.47% |
| Mendus AB (publ) | 129.13 Million SEK | 79.24% |
| Lipum AB (publ) | 37.3 Million SEK | 28.139% |
| NextCell Pharma AB | -576.01 Thousand SEK | 4754.187% |
| Simris Alg AB (publ) | 38.64 Million SEK | 30.622% |
| Elicera Therapeutics AB (publ) | 28.32 Million SEK | 5.357% |
| Active Biotech AB (publ) | 44.8 Million SEK | 40.171% |
| Amniotics AB (publ) | 29.07 Million SEK | 7.784% |
| Asarina Pharma AB (publ) | 14.65 Million SEK | -82.959% |
| BioArctic AB (publ) | 89.62 Million SEK | 70.088% |
| Cantargia AB (publ) | 290.01 Million SEK | 90.756% |
| Scandinavian ChemoTech AB (publ) | 21.89 Million SEK | -22.443% |
| CombiGene AB (publ) | 44.14 Million SEK | 39.269% |
| Diamyd Medical AB (publ) | 142.98 Million SEK | 81.251% |
| Genovis AB (publ.) | 88.19 Million SEK | 69.603% |
| Guard Therapeutics International AB (publ) | 115.07 Million SEK | 76.703% |
| Isofol Medical AB (publ) | 7.26 Million SEK | -268.864% |
| Intervacc AB (publ) | 79.78 Million SEK | 66.398% |
| Kancera AB (publ) | 63.07 Million SEK | 57.498% |
| Karolinska Development AB (publ) | 5.51 Million SEK | -385.758% |
| LIDDS AB (publ) | 27.75 Million SEK | 3.398% |
| Lipigon Pharmaceuticals AB (publ) | 7.25 Million SEK | -269.575% |
| Magle Chemoswed Holding AB (publ) | 135.91 Million SEK | 80.275% |
| OncoZenge AB (publ) | 15.9 Million SEK | -68.557% |
| Saniona AB (publ) | 1.07 Million SEK | -2389.229% |
| Vicore Pharma Holding AB (publ) | 321.5 Million SEK | 91.661% |
| Xbrane Biopharma AB (publ) | 357.62 Million SEK | 92.504% |
| Xintela AB (publ) | 57.31 Million SEK | 53.226% |
| Xspray Pharma AB (publ) | 181.73 Million SEK | 85.248% |
| Ziccum AB (publ) | 27.87 Million SEK | 3.835% |
| Modus Therapeutics Holding AB (publ) | 16.4 Million SEK | -63.46% |
| Alligator Bioscience AB (publ) | 307.09 Million SEK | 91.27% |
| Sprint Bioscience AB (publ) | 42.63 Million SEK | 37.115% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 17.68 Million SEK | -51.609% |
| Corline Biomedical AB | 30.16 Million SEK | 11.134% |
| IRLAB Therapeutics AB (publ) | 58.03 Million SEK | 53.802% |
| Bio-Works Technologies AB (publ) | 83.16 Million SEK | 67.766% |
| Aptahem AB (publ) | 10.01 Million SEK | -167.743% |
| Infant Bacterial Therapeutics AB (publ) | 134.69 Million SEK | 80.096% |
| Fluicell AB (publ) | 28.61 Million SEK | 6.318% |
| Biovica International AB (publ) | 133.72 Million SEK | 79.952% |
| Spago Nanomedical AB (publ) | 19.79 Million SEK | -35.467% |
| AcouSort AB (publ) | 25.87 Million SEK | -3.606% |
| Abliva AB (publ) | 27.86 Million SEK | 3.793% |
| Egetis Therapeutics AB (publ) | 193.5 Million SEK | 86.145% |
| 2cureX AB (publ) | 36.51 Million SEK | 26.587% |
| I-Tech AB | 40.14 Million SEK | 33.225% |
| Hansa Biopharma AB (publ) | 859.44 Million SEK | 96.881% |
| Cyxone AB (publ) | 28.21 Million SEK | 4.98% |
| ExpreS2ion Biotech Holding AB (publ) | 109.36 Million SEK | 75.487% |
| Nanologica AB (publ) | 69.88 Million SEK | 61.64% |
| SynAct Pharma AB | 224.49 Million SEK | 88.058% |
| Annexin Pharmaceuticals AB (publ) | 44.17 Million SEK | 39.313% |
| BioInvent International AB (publ) | 441.4 Million SEK | 93.926% |
| Stayble Therapeutics AB (publ) | 23.95 Million SEK | -11.917% |
| Alzinova AB (publ) | 36.39 Million SEK | 26.341% |
| Oncopeptides AB (publ) | 289.74 Million SEK | 90.747% |
| Pila Pharma AB (publ) | 7.85 Million SEK | -241.243% |
| Ascelia Pharma AB (publ) | 110.91 Million SEK | 75.829% |
| Diagonal Bio AB (publ) | 14.7 Million SEK | -82.374% |